PAREXEL to Acquire ExecuPharm

Published on: 

Applied Clinical Trials

Acquisition of function service provider ExecuPharm addresses what PAREXEL sees as a growing trend among biopharm companies to use combinations of outsourcing models.

PAREXEL has entered into a definitive agreement to acquire ExecuPharm, a global functional service provider (FSP) serving the biopharmaceutical industry. The acquisition is intended to address sponsors’ growing usage of combining different outsourcing models. The FSP offers the ability to outsource specific trial functions tactically, on a particular trial, or strategically to constitute or supplement an entire department.

Read the full release.